Drug
Nalbuphine sebacate clinical trials
Also written Naldebain and LT1001.
Keep track of what changes. Save the nalbuphine sebacate studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
15 studies that test it; most in 2021 (3)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
- Pain
- 1
Who runs them
Industry 4 · Other 11
Lumosa Therapeutics Co., Ltd. (3) · E-DA Hospital (3) · Kaohsiung Medical University Chung-Ho Memorial Hospital (2) · Tri-Service General Hospital (1) · Cathay General Hospital (1) · Sinew Pharma Inc. (1) · Thammasat University (1) · Dalin Tzu Chi General Hospital (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses nalbuphine sebacate is read from its arms, and is right about nine times in ten.
Testing it · 15
- Dinalbuphine Sebacate in Postoperative Pain Control After TKANot yet recruitingPhase 4Thammasat UniversityNCT07140510Written as Dinalbuphine Sebacate
- Dinalbuphine Ester (Naldebain) for Pain Management After Cesarean SectionRecruitingPhase 2/3Dalin Tzu Chi General HospitalNCT06344169Written as Sebacoyl Dinalbuphine Ester
- A Novel, Potent and Non-addictive Analgesic of Combinations for Knee Replacement Moderate to Severe Pain ManagementEnrolling by invitationPhase 2Sinew Pharma Inc.NCT05842733Written as Naldebain
- A Study of Intramuscular Sebacoyl Dinalbuphine Ester for Post-Hemorrhoidectomy Pain ManagementCompletedPhase 2/3Lumosa Therapeutics Co., Ltd.NCT02468128Written as Sebacoyl Dinalbuphine Ester
- PO Pain Management With Extended-release Dinalbuphine Sebacate in Patients Undergoing Arthroscopic Shoulder SurgeryCompletedPhase 4Tri-Service General HospitalNCT05115955Written as DS group
- Postoperative Pain Management on Uvulopalatopharyngoplasty PatientsStatus unknownPhase 4Li-Jen HsinNCT05825495Written as Dinalbuphine sebacate
- Naldebain for Pain Management After Knee ArthroplastyCompletedPhase 4Kaohsiung Medical University Chung-Ho Memorial HospitalNCT05266027Written as Nalbuphine Sebacate (Naldebain)
- Naldebain for Pain Management of Laparoscopic CholecystectomyCompletedPhase 2/3E-DA HospitalNCT04808544Written as Dinalbuphine sebacate
- Naldebain for Control of Post-Cesarean Section PainStatus unknownPhase 2E-DA HospitalNCT05187520Written as Naldebain®
- Naldebain for Pain Control After Bariatric SurgeryStatus unknownPhase 2/3E-DA HospitalNCT04651361Written as Dinalbuphine sebacate
- A Bioavailability Study of NALDEBAIN ER Injection and Nalbuphine Injection in Healthy Volunteers.CompletedPhase 1Lumosa Therapeutics Co., Ltd.NCT04256434Written as Dinalbuphine sebacate
- Comparison of the Efficacy and Safety of NALDEBAIN With Conventional Treatment After Laparoscopic CholecystectomyCompletedPhase 4Cathay General HospitalNCT03713216Written as Naldebain
- NALDEBAIN for Postoperative Pain Management in Take Down of AnastomosisStatus unknownPhase 4China Medical University HospitalNCT03854851Written as Naldebain
- The Efficacy and Safety of NALDEBAIN for the Treatment of Post-Laparotomy SurgeryStatus unknownPhase 4Kaohsiung Medical University Chung-Ho Memorial HospitalNCT03296488Written as Nalbuphine Sebacate
- A Bioavailability Study of Sebacoyl Dinalbuphine Ester IM Injection in Healthy VolunteersCompletedPhase 1Lumosa Therapeutics Co., Ltd.NCT02446301Written as SDE
Codes
What other systems call nalbuphine sebacate · ClinicalTrials.gg INT014807
- UNII (FDA) 464OXX39Y6DINALBUPHINE SEBACATEConfirmed FDA, Wikidata
- Wikidata Q27258899nalbuphine sebacateConfirmed FDA, Wikidata
- NCI Thesaurus C166728Dinalbuphine SebacateOne source FDA
- DrugBank DB15341One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 464OXX39Y6 | DINALBUPHINE SEBACATE | Confirmed FDA, Wikidata |
| Wikidata | Q27258899 | nalbuphine sebacate | Confirmed FDA, Wikidata |
| NCI Thesaurus | C166728 | Dinalbuphine Sebacate | One source FDA |
| DrugBank | DB15341 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.